Can positron emission tomography with [18 F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?-Reference-Cited by-同舟云学术

Can positron emission tomography with [18 F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?

Published:2001-11 Issue:2 Volume:115 Page:272-278
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

Spaepen Karoline,Stroobants Sigrid,Dupont Patrick,Thomas José,Vandenberghe Peter,Balzarini Jan,De Wolf-Peeters Christine,Mortelmans Luc,Verhoef Gregor

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1365-2141.2001.03169.x/fullpdf

Reference36 articles.

1. Problems in Hodgkin's disease management;Aisenberg;Blood,1999

2. Whole-body 2-18F-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease;Bangerter;Annals of Oncology,1998

3. Incidence of second cancers in patients treated for Hodgkin's disease;Boivin;Journal of the National Cancer Institute,1995

4. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma;De Wit;Annals of Oncology,1997

5. Lymphoma: Predictive value of Ga-67 scintigraphy after treatment;Front;Radiology,1992

Cited by 160 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PET/CT in Hodgkin Lymphoma: An Update;Seminars in Nuclear Medicine;2023-05

2. The Role of Post-treatment FDG-PET/CT Scanning after the First-line Chemotherapy in Predicting Prognosis in Patients with Hodgkin Disease and High-grade Non-Hodgkin Lymphoma: A Comparative Study with Clinical Prognostic Risk Scoring Data;Bezmialem Science;2022-06-29

3. Linfoma de Hodgkin en niños y adolescentes;EMC - Pediatría;2022-06

4. Diagnostic Applications of Nuclear Medicine: Lymphomas;Nuclear Oncology;2022

5. Diagnostic Applications of Nuclear Medicine: Lymphomas;Nuclear Oncology;2022